CytomX Therapeutics is an early stage, privately-funded biotechnology company developing proteolytically-activated biotherapeutics. Our mission, with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
______________________________
As of February 1, 2008 the bioseparation technology of CytomX, LLC has become Cynvenio Biosystems.
You can find it here:
www.cynvenio.com
